JW Holdings Sets Up Exclusive Booth at CPHI to Showcase CDMO Capabilities

The World's Largest Pharmaceutical and Bio Exhibition
Featuring Prescription and Over-the-Counter Drugs

JW Holdings announced on the 24th that it will participate in the world's largest pharmaceutical and bio exhibition, the 'Convention on Pharmaceutical Ingredients 2023 (CPHI 2023),' held in Barcelona, Spain, for three days from the 24th to the 26th (local time).

CPHI is an exhibition held annually in major cities around the world, regarded as a global exchange event among healthcare companies covering not only raw materials and finished pharmaceuticals but also pharmaceutical packaging, equipment, and logistics. This event is expected to attract more than 47,000 industry professionals from over 150 countries worldwide.

JW Holdings plans to raise its global market recognition by setting up a solo booth at this event to introduce pharmaceuticals from its affiliates such as JW Pharmaceutical and JW Life Science. At the same time, it will focus on promoting key product lines, including prescription drugs and over-the-counter medicines, to potential customers in the European market.

Additionally, JW Holdings will promote its pharmaceutical plant, the specialized systems and know-how that operate it, and showcase its contract manufacturing (CMO) and contract development and manufacturing (CDMO) capabilities to global clients.

Since entering the European market in 2018, JW Holdings has continued local sales by exporting 'Winnerf,' a 3-chamber total parenteral nutrition solution produced by JW Life Science. It is also expanding its presence in the global market for finished raw material pharmaceuticals in the carbapenem antibiotic category. JW Pharmaceutical succeeded in developing the world's first generic imipenem in 2004 and has built a production portfolio for the entire carbapenem series by independently synthesizing meropenem, ertapenem, and doripenem.

A JW Holdings official stated, "Based on the global competitiveness accumulated over a long period, JW Group is striving to expand its influence in the European market," adding, "Through this event, we will strengthen collaboration with global partners and promote JW Group's excellent pharmaceuticals to the world market."

This content was produced with the assistance of AI translation services.